Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Reducing Agents

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    51 result(s) found for: Reducing Agents. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2022-002741-18 Sponsor Protocol Number: GS-US-611-6273 Start Date*: 2022-11-25
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5245 for the Treatment of COVID-19 in Participants With High-Risk for Disease Progression
    Medical condition: Coronavirus disease 2019 (COVID-19) in patients who have a high risk of developing serious or severe illness
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Ongoing) BG (Completed) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-000046-19 Sponsor Protocol Number: RIVAROXHFA3001/BAY59-7939/16302 Start Date*: 2013-08-23
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Oral Rivaroxaban with Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Sub...
    Medical condition: Prevention of death, heart attack and stroke in patients with chronic heart failure and significant coronary artery disease following a hospitalization for exacerbation of heart failure.
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) CZ (Completed) DE (Completed) NL (Completed) BG (Completed) PL (Completed) HU (Completed) SE (Completed) IT (Completed) GB (Completed) EE (Completed) LT (Completed) PT (Completed) DK (Completed) LV (Completed) SK (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2005-000487-11 Sponsor Protocol Number: CRFB002D2201 Start Date*: 2005-09-30
    Sponsor Name:Novartis Pharma Service AG
    Full Title: A randomized, double-masked, multicenter, phase II study assessing the safety and efficacy of two concentrations of ranibizumab (intravitreal injections) compared with non-treatment control for the...
    Medical condition: Male and female patients >18 years of age with either type 1 or type 2 diabetes mellitus with stable HbA1c levels between 6.5 and 10% and diabetic macular edema with center involvement in at least ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) GB (Completed) AT (Completed) ES (Completed) IT (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2004-001054-84 Sponsor Protocol Number: 2004/W/GI/02 Start Date*: 2005-02-16
    Sponsor Name:NHS Lothian- University Hospitals Division
    Full Title: A comparison of the efficacy of dietary hydroxypropylcellulose and questran as therapeutic agents in bile acid induced diarrhoea
    Medical condition: these patients will have bile acid induced diarrhoea identified by an increased serum 7a-OH-cholestenone. and will have a history of one of 1. ileal resection 2. idiopathic bile acid diarrhoea.3. ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-003612-30 Sponsor Protocol Number: 0904HELIOX Start Date*: 2005-11-23
    Sponsor Name:Barts and the London NHS Trust
    Full Title: A comparison of Helium-oxygen mixture (Heliox) with an oxygen-air mixture in reducing the work of breathing during weaning from mechanical ventilation.
    Medical condition: Patients admitted to the intensive care unit who are in the recovery phase of their illness and are weaning from mechanical ventilation.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-004260-22 Sponsor Protocol Number: ELFIN01 Start Date*: 2013-08-28
    Sponsor Name:University of Oxford
    Full Title: A multi-centre randomised placebo-controlled trial of prophylactic enteral lactoferrin supplementation to prevent late-onset invasive infection in very preterm infants.
    Medical condition: Late onset invasive infection in very preterm infants
    Disease:
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2022-001539-10 Sponsor Protocol Number: UX007-CL302 Start Date*: 2022-12-27
    Sponsor Name:Ultragenyx Pharmaceutical Inc.
    Full Title: A Randomized, Double-blind, Multicenter Study to Determine the Effect of Triheptanoin Compared with Even-chain, Medium-chain Triglycerides (MCT) on Major Clinical Events (MCEs) in Pediatric Patient...
    Medical condition: Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10077951 Fatty acid oxidation disorder PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) PL (Ongoing) CZ (Ongoing) DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-002349-23 Sponsor Protocol Number: 8232-CL-0004 Start Date*: 2015-01-26
    Sponsor Name:Astellas Pharma Europe BV (APEB)
    Full Title: A Phase 2, Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme inhibitor (ACEi) or Angiotensin Recep...
    Medical condition: Diabetic nephropathy
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) GB (Completed) HU (Completed) CZ (Completed) DE (Completed) BE (Completed) IT (Completed) NL (Completed) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2018-004889-34 Sponsor Protocol Number: NN7415-4311 Start Date*: 2019-10-07
    Sponsor Name:Novo Nordisk A/S
    Full Title: Efficacy and Safety of Concizumab prophylaxis in patients with haemophilia A or B with inhibitors
    Medical condition: Haemophilia A with inhibitors Haemophilia B with inhibitors
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10053751 Hemophilia A with anti factor VIII LLT
    20.0 10010331 - Congenital, familial and genetic disorders 10053752 Hemophilia B with anti factor IX LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male
    Trial protocol: DK (Trial now transitioned) SE (Trial now transitioned) AT (Completed) FR (Ongoing) PT (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) SK (Completed) NO (Ongoing) BG (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) HR (Ongoing) IT (Restarted)
    Trial results: (No results available)
    EudraCT Number: 2006-004204-39 Sponsor Protocol Number: 108701 Start Date*: 2007-02-01
    Sponsor Name:GLAXO SMITHKLINE
    Full Title: A randomized, open label, multicentre study to compare the pharmaco-economic implications of an analgesia based regimen with remifentanil and a conventional sedation based regimen using propofol in...
    Medical condition: Medical and post surgical ICU patient requiring analgesia and sedation.
    Disease: Version SOC Term Classification Code Term Level
    6.1 10039897 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-001831-73 Sponsor Protocol Number: REDOXS© Start Date*: 2009-03-12
    Sponsor Name:Kingston General Hospital, Queen's University of Kingston
    Full Title: REducing Deaths due to OXidative Stress The REDOXS© Study A 2×2 factorial randomized trial of glutamine and antioxidant supplementation in critically ill patients
    Medical condition: Critically ill patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-002472-99 Sponsor Protocol Number: EVT302/3009 Start Date*: 2008-08-12
    Sponsor Name:Evotec Neurosciences GmbH
    Full Title: A phase II multicenter, randomised, double-blind, parallel group, placebo-controlled, study to evaluate the effectiveness of EVT 302 in smoking cessation, effect on its own and in combination with ...
    Medical condition: Male or female subjects who are chronic smokers, but motivated to quit smoking will be recruited.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-004191-35 Sponsor Protocol Number: GLYCO-1B Start Date*: 2019-04-12
    Sponsor Name:Cliniques universitaires Saint-Luc
    Full Title: Evaluation of the safety and efficacy of administration of Empagliflozin in a new treatment for neutropenia in patients with Glycogen Storage Disease type 1b (GSD1b) and G6PC3 deficiency.
    Medical condition: (1) Severe Congenital Neutropenia type 4 (SNC4) due to a deficiency in G6PC3, a phosphatase of the endoplasmic also known a Ubiquitous glucose-6-phosphatase and (2) the neutropenia in Glycogen Sto...
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000225-51 Sponsor Protocol Number: ITP-NODAT Start Date*: 2012-11-21
    Sponsor Name:Fundació Institut Mar d'investigacions Mediques
    Full Title: Insulin Therapy for the Prevention of New Onset Diabetes after Transplantation (ITP-NODAT) Prospective Study in Non-Diabetic De Novo Kidney Transplant Recipients
    Medical condition: Previously non-diabetic end stage renal disease patients undergoing kidney transplantation.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2010-021718-41 Sponsor Protocol Number: 214868-004-03 Start Date*: 2011-03-03
    Sponsor Name:Allergan Ltd
    Full Title: A Pilot, Multicenter, Double-blind, Placebo-controlled, Dose-escalation Study of the Safety and Efficacy of AGN-214868 in Patients with Idiopathic Overactive Bladder and Urinary Incontinence
    Medical condition: To evaluate the safety and efficacy of AGN-214868 compared with placebo in the treatment of patients with idiopathic overactive bladder (IOAB) and urinary incontinence.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2022-001134-11 Sponsor Protocol Number: 1305-0023 Start Date*: 2022-11-22
    Sponsor Name:Boehringer Ingelheim International GmbH
    Full Title: A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
    Medical condition: Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
    Disease: Version SOC Term Classification Code Term Level
    23.1 10038738 - Respiratory, thoracic and mediastinal disorders 10084309 Progressive fibrosing interstitial lung disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Ongoing) ES (Ongoing) AT (Ongoing) DE (Ongoing) NO (Ongoing) EE (Ongoing) FI (Ongoing) SE (Ongoing) PT (Ongoing) NL (Ongoing) HU (Ongoing) DK (Ongoing) GR (Ongoing) IT (Ongoing) HR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-001419-29 Sponsor Protocol Number: HRVCTA1 Start Date*: 2011-05-05
    Sponsor Name:Universitätsklinik für Radiodiagnostik
    Full Title: Influence of iodinated contrast agents on heart rate variation and diagnostic image quality during CT angiography of the coronary arteries
    Medical condition: CT angiography of the coronary arteries
    Disease: Version SOC Term Classification Code Term Level
    13.1 10007541 - Cardiac disorders 10011082 Coronary artery disorders HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2021-000319-21 Sponsor Protocol Number: ClonDO Start Date*: 2021-12-20
    Sponsor Name:Charité – Universitätsmedizin Berlin
    Full Title: Treating Nightmares in Posttraumatic Stress Disorder with the α-adrenergic Agents Clonidine and Doxazosin: A Randomized-Controlled Feasibility Study (ClonDoTrial)
    Medical condition: Posttraumatic Stress Disorder
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-001898-25 Sponsor Protocol Number: DAR-311 Start Date*: 2006-09-21
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group Study to Evaluate the Effica...
    Medical condition: Resistant hypertension
    Disease: Version SOC Term Classification Code Term Level
    8.1 10038274 Refractory hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) DE (Completed) GB (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-005330-20 Sponsor Protocol Number: WA20495 Start Date*: 2007-06-07
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A randomized, double-blind, parallel group, international study to evaluate the safety and efficacy of ocrelizumab compared to placebo in patients with active rheumatoid arthritis who have an in...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10028395 Musculoskeletal and connective tissue disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) FR (Completed) HU (Completed) ES (Temporarily Halted) CZ (Completed) NL (Completed) SI (Completed) SE (Completed) IT (Completed) SK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 07:28:30 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA